Since constitutive NF-κB activity drives oncogenesis by upregulating antiapoptotic genes [2,10], we sought to overcome this barrier by targeting the non-redundant, cancer-specific downstream effectors of the oncogenic NF-κB survival function, rather than NF-κB itself [11]. The gene discussed is NFKB1; the disease is cancer.